RT Journal Article
SR Electronic
T1 A quantitative systems pharmacology workflow towards optimal design and biomarker stratification of atopic dermatitis clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.01.23292105
DO 10.1101/2023.07.01.23292105
A1 Go, Natacha
A1 Arsène, Simon
A1 Faddeenkov, Igor
A1 Galland, Théo
A1 Martis B., Shiny
A1 Lefaudeux, Diane
A1 Wang, Yishu
A1 Etheve, Loic
A1 Jacob, Evgueni
A1 Monteiro, Claudio
A1 Bosley, Jim
A1 Sansone, Caterina
A1 Pasquali, Christian
A1 Lehr, Lorenz
A1 Kulesza, Alexander
YR 2023
UL http://medrxiv.org/content/early/2023/07/03/2023.07.01.23292105.abstract
AB Background The development of atopic dermatitis (AD) drugs is confronted by many disease phenotypes and trial design options, which are hard to explore experimentally.Objective Optimize AD trial design using simulations.Methods We constructed a quantitative systems pharmacology (QSP) model of AD and standard of care (SoC) treatments and generated a phenotypically diverse virtual population whose parameter distribution is derived from known relationships between AD biomarkers and disease severity and b) calibrated using disease severity evolution under SoC regimens.Results We applied this workflow to the immunomodulator OM-85, currently being investigated for its potential use in AD, and calibrated investigational treatment model with the efficacy profile of an existing trial (thereby enriching it with plausible marker levels and dynamics). We assessed the sensitivity of trial outcomes to trial protocol and found that for this particular example, a) the choice of endpoint is more important than the choice of dosing-regimen and b) patient selection by model-based responder enrichment could increase the expected effect size. A global sensitivity analysis reveals that only a limited subset of baseline biomarkers is needed to predict the drug response of the full virtual populationConclusion This AD QSP workflow built around knowledge of marker-severity relationships as well as SoC efficacy can be tailored to specific development cases so as to optimize several trial protocol parameters and biomarker-stratificaiton and therefore holds promise to become a powerful model-informed drug development tool.Key MessagesDisease and treatment models can quantify pre-existing knowledge about complex immune diseases such as atopic dermatitis and drug’s efficacy data under one common umbrella.Embedding QSP models into trial simulation setup can give insight into clinical trial optimization.Complex QSP models can help with patient selection and biomarker identification.Capsule Summary This study shows the relevance of QSP model and computer simulations in assisting clinical development in the field of atopic dermatitis by assessing the impact of trial protocol on treatment effect and guiding biomarker programs.Competing Interest StatementN.G., S.A., I.F., T.G., S.M.B., D.L., Y.W., L.E., E.J., C.M., J.B., and A.K. are employees of Novadiscovery. C.S., C.P., and L.L are employees of OM Pharma.Funding StatementNovadiscovery and OM Pharma funded the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll information needed to reproduce the simulations are described in the references of this manuscript, and the supplementary information. Access to the computational model code, documentation and simulation results are available on Jinko.ai platform upon request to the corresponding author. R scripts developed for analysis of simulation results and producing the figures are also available upon resonable request.ADAtopic dermatitisSoCStandard of careTCSTopical corticosteroidsODEOrdinary differential equationQSPQuantitative systems pharmacologyPBPKPhysiologically based pharmacokineticPDPharmacodynamicsABAbsolute benefitSCORADScoring atopic dermatitisEASIEczema area and severity index